Aevius Spins Out of Mass General With $22M

The AI startup, launched by Mass General Brigham researchers, will sell technology that models each patient's full medical history.

Updated on Nov. 17, 2026 in Healthcare

Aevius Spins Out of Mass General With $22M

Mass General Brigham has spun off Aevius, an AI startup that launched on November 17, 2026, with $22 million in seed funding led by Insight Partners. The company builds AI models that learn from a patient's full medical history and is selling its technology to health systems, payers, and life sciences companies.

Why it matters

The spinout moves research developed at Mass General Brigham toward commercial use in healthcare, a field where patient data is fragmented across notes, imaging, and biomarkers. Its founders previously worked on Modella AI, which AstraZeneca acquired, giving the team prior experience in bringing medical AI to market.

Aevius raised $22 million in seed funding led by Insight Partners, a firm reporting more than $90 billion in regulatory assets under management across more than 900 companies. Early customers and clinical validation of the company's models have not been detailed.

The players

Mass General Brigham

A major Boston-based academic health system headquartered in Somerville, Massachusetts, whose research is the basis for the new spinout.

Insight Partners

A global venture capital and private equity firm that led Aevius's seed round and reports investments in more than 900 companies.

Eric Topol

A prominent cardiologist and digital medicine researcher who chairs Aevius's scientific advisory board.

The details

Aevius models combine clinical notes, imaging, biomarkers, and other data into a continuously updated, computable representation of each patient. The company is selling this technology to health systems, payers, and life sciences companies, and its scientific advisory board is chaired by Eric Topol.

Timeline

  1. November 17, 2026: Aevius launches with $22 million in seed funding.

Market Landscape

The founding team previously built Modella AI, which AstraZeneca acquired, placing Aevius in a market where pharmaceutical companies have bought medical AI developers. Aevius now targets health systems and payers directly rather than drug developers alone.

Patients at Mass General Brigham and other health systems that adopt Aevius technology may see care plans shaped by predictive models of disease progression. The extraction does not establish when or whether these tools will reach individual patients.

The takeaway

Aevius shows how academic medical research can move into commercial health AI through a spinout led by experienced founders. Readers should watch whether health systems adopt its models and what clinical evidence follows.

Further reading

Explore more Massachusetts healthcare coverage to see how regional health systems are commercializing research.